XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Accounts Receivable
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Accounts Receivable of $7.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.81M, a 73.06% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $5.25M, a 11.33% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$2.70M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $703.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $10.63M, a 773.15% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $1.22M, a 85.44% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $8.37M, a 37.44% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $13.37M, a 114.43% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.05M 10-Q · filed 2026-08-06 | $4.35M derived: sum of 3 quarters · filed 2026-08-06 | $5.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.25M 10-Q · filed 2026-05-07 | $2.54M derived: sum of 2 quarters · filed 2026-05-07 | $3.25M derived: sum of 3 quarters · filed 2026-05-07 | $9.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$2.00M derived: sum of 2 quarters · filed 2026-03-02 | $4.72M derived: sum of 3 quarters · filed 2026-08-06 | $10.63M 10-K · filed 2026-03-02 |
| 2025-09-30 | $703.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.42M derived: sum of 2 quarters · filed 2026-08-06 | $13.34M 10-Q · filed 2025-11-06 | $12.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $12.63M 10-Q · filed 2026-08-06 | $11.91M derived: sum of 3 quarters · filed 2026-08-06 | $10.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.92M 10-Q · filed 2026-05-07 | $5.19M derived: sum of 2 quarters · filed 2026-05-07 | $3.89M derived: sum of 3 quarters · filed 2026-05-07 | $8.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$723.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$2.02M derived: sum of 2 quarters · filed 2026-03-02 | $3.00M derived: sum of 3 quarters · filed 2026-03-02 | $1.22M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.72M derived: sum of 2 quarters · filed 2025-11-06 | $1.94M 10-Q · filed 2025-11-06 | -$4.83M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.24M 10-Q · filed 2025-08-07 | -$3.53M derived: sum of 3 quarters · filed 2026-03-02 | $12.21M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$1.78M 10-Q · filed 2025-05-08 | -$8.55M derived: sum of 2 quarters · filed 2026-03-02 | $7.19M derived: sum of 3 quarters · filed 2026-03-02 | $6.55M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.97M derived: sum of 2 quarters · filed 2026-03-02 | $8.34M derived: sum of 3 quarters · filed 2026-03-02 | $8.37M 10-K · filed 2026-03-02 |
| 2023-09-30 | $15.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $15.11M derived: sum of 2 quarters · filed 2024-11-08 | $15.14M 10-Q · filed 2024-11-08 | $18.45M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$635.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$605.00K 10-Q · filed 2024-08-08 | $2.71M derived: sum of 3 quarters · filed 2025-03-06 | $4.47M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $30.00K 10-Q · filed 2024-05-09 | $3.34M derived: sum of 2 quarters · filed 2025-03-06 | $5.10M derived: sum of 3 quarters · filed 2025-03-06 | $7.48M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $5.07M derived: sum of 2 quarters · filed 2025-03-06 | $7.45M derived: sum of 3 quarters · filed 2025-03-06 | $13.37M 10-K · filed 2025-03-06 |
| 2022-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.13M derived: sum of 2 quarters · filed 2023-11-09 | $10.06M 10-Q · filed 2023-11-09 | $9.61M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $8.30M 10-Q · filed 2023-08-08 | $7.85M derived: sum of 3 quarters · filed 2024-03-06 | $9.12M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $5.93M 10-Q · filed 2023-05-09 | $5.48M derived: sum of 2 quarters · filed 2024-03-06 | $6.74M derived: sum of 3 quarters · filed 2024-03-06 | $10.10M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$449.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $817.00K derived: sum of 2 quarters · filed 2024-03-06 | $4.17M derived: sum of 3 quarters · filed 2024-03-06 | $6.24M 10-K · filed 2024-03-06 |
| 2021-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.62M derived: sum of 2 quarters · filed 2022-11-09 | $6.69M 10-Q · filed 2022-11-09 | $1.63M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $5.42M 10-Q · filed 2022-08-10 | $367.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $2.06M 10-Q · filed 2022-05-11 | -$2.99M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $2.18M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $7.24M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |